The emergence of mephedrone together with other artificial cathinones has introduced problems for lawmakers and regulatory businesses tasked with managing the proliferation of new psychoactive substances. The dynamic character of artificial drug creation, coupled with the ability of chemists to change molecular buildings to evade legal limitations,